Journal Article

Prolongation of repolarization in pre-clinical investigations and phase I/II clinical trials: what should be done?

G. Sponer

in European Heart Journal Supplements

Published on behalf of European Society of Cardiology

Volume 3, issue suppl_K, pages K101-K104
Published in print September 2001 | ISSN: 1520-765X
Published online September 2001 | e-ISSN: 1554-2815 | DOI: http://dx.doi.org/10.1016/S1520-765X(01)90013-6
Prolongation of repolarization in pre-clinical investigations and phase I/II clinical trials: what should be done?

Show Summary Details

Preview

In the past, some non-cardiovascular drugs have been identified as prolonging repolarization and evoking torsade de pointes. Concerns prompted the health authorities to request detailed investigations targeted on this issue. In particular, in vitro and in vivo pre-clinical studies are regarded as mandatory in order to assess properly the potential risk of new compounds. However, appropriate assessment is only possible if the methods used are standardized and validated, which cannot currently be completely guaranteed. Additionally, a suitable threshold should also be specified in pre-clinical test systems. If some findings indicate prolongation of repolarization, further investigations are needed in order to evaluate the potential risk or to get more insight into the mode of action. However, withdrawal of the compound from further development at any stage is another alternative in order to spare resources and to avoid regulatory problems. In any case, a proper evaluation of the benefit-risk ratio is mandatory when findings indicate that a new compound may prolong repolarization.

Keywords: Action potential; QT prolongation; drug development

Journal Article.  0 words. 

Subjects: Cardiovascular Medicine

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.